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Rotterdam, the Netherlands; New York, New York; Ferrara, Italy; Bern, Switzerland; and
Natick, MassachusettsObjectives This study sought to validate the Logistic Clinical SYNTAX (Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery) score in patients with non–ST-segment
elevation acute coronary syndromes (ACS), in order to further legitimize its clinical application.
Background The Logistic Clinical SYNTAX score allows for an individualized prediction of 1-year
mortality in patients undergoing contemporary percutaneous coronary intervention. It is composed
of a “Core” Model (anatomical SYNTAX score, age, creatinine clearance, and left ventricular ejection
fraction), and “Extended” Model (composed of an additional 6 clinical variables), and has previously
been cross validated in 7 contemporary stent trials (>6,000 patients).
Methods One-year all-cause death was analyzed in 2,627 patients undergoing percutaneous coronary
intervention from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Mortality predictions from the Core and Extended Models were studied with respect to discrimination,
that is, separation of those with and without 1-year all-cause death (assessed by the concordance [C]
statistic), and calibration, that is, agreement between observed and predicted outcomes (assessed with
validation plots). Decision curve analyses, which weight the harms (false positives) against beneﬁts (true
positives) of usinga risk score tomakemortality predictions,wereundertaken to assess clinical usefulness.
Results In the ACUITY trial, the median SYNTAX score was 9.0 (interquartile range 5.0 to 16.0);
approximately 40% of patients had 3-vessel disease, 29% diabetes, and 85% underwent drug-eluting
stent implantation. Validation plots conﬁrmed agreement between observed and predicted mortality.
The Core and Extended Models demonstrated substantial improvements in the discriminative ability
for 1-year all-cause death compared with the anatomical SYNTAX score in isolation (C-statistics:
SYNTAX score: 0.64, 95% conﬁdence interval [CI]: 0.56 to 0.71; Core Model: 0.74, 95% CI: 0.66 to 0.79;
Extended Model: 0.77, 95% CI: 0.70 to 0.83). Decision curve analyses conﬁrmed the increasing ability to
correctly identify patients who would die at 1 year with the Extended Model versus the Core Model
versus the anatomical SYNTAX score, over a wide range of thresholds for mortality risk predictions.
Conclusions Compared to the anatomical SYNTAX score alone, the Core and Extended Models of the
Logistic Clinical SYNTAX score more accurately predicted individual 1-year mortality in patients
presenting with non–ST-segment elevation acute coronary syndromes undergoing percutaneous
coronary intervention. These ﬁndings support the clinical application of the Logistic Clinical SYNTAX
score. (J Am Coll Cardiol Intv 2013;6:737–45) ª 2013 by the American College of Cardiology
Foundation
Farooq et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 7 , 2 0 1 3
Validation of the Logistic Clinical SYNTAX Score J U L Y 2 0 1 3 : 7 3 7 – 4 5
738The SYNTAX (Synergy Between Percutaneous Coronary elevation acute coronary syndromes (ACS), in order to
Intervention With Taxus and Cardiac Surgery) score is as an
objective, anatomical-based tool to determine the complexity of
coronary artery disease and guide decision making between
cardiac surgery and percutaneous coronary intervention (PCI)
(1–5). Since the SYNTAX trial, numerous validation studies
have conﬁrmed the SYNTAX score to be an independent
predictor of long-termmortality in abroad rangeof patient types
(6–8). The use of the SYNTAX score is now advocated in both
the U.S. and European revascularization guidelines (9,10). In
addition, theU.S.Food andDrugAdministrationmandates the
SYNTAX score as entry criteria in ongoing contemporary stent
and structural heart disease trials, investigating percutaneous left
main coronary intervention (EXCEL [Evaluation of XIENCE
PRIME Everolimus Eluting Stent System (EECSS) or
XIENCE V EECSS Versus Coronary Artery Bypass Surgery
for Effectiveness of Left Main Revascularizations] Clinical
Trial; NCT01205776) (11) and transcatheter aortic valve
implantation (SURTAVI [Safety and Efﬁcacy Study of theFrom the *Department of Interventi
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The lack of clinical variables,
and the lack of a more individual-
ized approach of the SYNTAX
scoredwithpatients categorized as
“low,” “intermediate,” or “high”
riskdhas recently been shown to
be potentially misleading. In a post
hoc analysis of the SYNTAX trial
(12), relatively higher- and lower-
risk patients were identiﬁed inthe low and high SYNTAX score groups, respectively. The
Logistic Clinical SYNTAX score (13) was designed to
overcome these limitations, by augmenting the anatomical
SYNTAX score with clinical variables, and to individualize
long-term (1-year) mortality predictions in patients undergoing
contemporary PCI.
The purpose of this study was to validate the Logistic
Clinical SYNTAX score in patients with non–ST-segmentonal Cardiology, Erasmus University Medical
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Methods
Study population. TheACUITY (AcuteCatheterization and
Urgent Intervention Triage Strategy) trial design has previ-
ously been described (14). In brief, this was a multicenter,
prospective, randomized trial of patients with moderate-
and high-risk non–ST-segment elevation ACS, managed
with an early invasive strategy. Coronary angiography was
performed in all patients within 72 h of randomization to
a speciﬁc anticoagulation regime undertaken during the
intervention. The choice of either bare-metal (BMS) or
drug-eluting stents (DES) was per operator discretion;
approximately 85% of the PCI population underwent DES
implantation. First-generation sirolimus-eluting or paclitaxel-
eluting stents were exclusively used ifDESwas to be implanted.
Dual antiplatelet therapy with aspirin and clopidogrel was
strongly recommended for at least 1 year. All major adverse
events were adjudicated by an independent clinical events
committee blinded to treatment assignment. In line with
a previous validation study of the anatomical SYNTAXscore in
the ACUITY trial (8), the subgroup of PCI patients in whom
quantitative coronary angiography was performed in the formal
angiographic substudy of the ACUITY trial (n ¼ 2,627) was
used for validation in the present study (15). All patients
underwent anatomical SYNTAX score analyses by 3 inter-
ventional cardiologists, appropriately trained for SYNTAX
score reading and blinded to the clinical outcomes (16).
Logistic Clinical SYNTAX score. The Logistic Clinical
SYNTAX score has previously been developed and cross-
validated (13) in a pooled population of 7 contemporary DES
trials (n ¼ 6,309) (2,17–23). It is composed of a Core Model
(consisting of the anatomical SYNTAX score, age, creatinine
clearance [CrCl], and left ventricular ejection fraction
[LVEF]), and an Extended Model (consisting of an addi-
tional 6 clinical variables) to improve the accuracy of 1-year
mortality predictions. During development and cross-
validation (13), the Core Model was shown to substantially
improve the predictive ability of the anatomical SYNTAX
score, with a minor incremental beneﬁt in improving
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739For validation purposes, all predictor values in the Core
Model were present in >85% of patients. For the additional
predictors of the Extended Model, all values were present in
>90% of patients, except peripheral vascular disease (PVD)
(not recorded) and body mass index (weight [100%,
n ¼ 2,627], height [36%, n ¼ 945]). The deﬁnition of PVD
was expanded to include previous transient ischemic attack
or cerebrovascular accident, because these variables repre-
sented extracardiac arteriopathy. This modiﬁcation to the
variable was rerun in the original development and cross-
validation population (13), with no change in predictive
performance of the Logistic Clinical SYNTAX score
(Fig. 1). Multiple imputation (5) of missing values was
undertaken using an imputation strategy that takes the
correlation between all potential predictors into account.
The method of chained equations with the Multivariate
Imputation by Chained Equations (MICE) algorithm in R
software (R Foundation for Statistical Computing, Vienna,
Austria) was used (23,24).Figure 1. The Logistic Clinical SYNTAX Score for the Prediction of 1-Year Death
Core (incorporating 4 variables) and Extended Model (incorporating a further 6 varia
criteria for the SYNTAX All-Comers trial: that is, left main stem (isolated or associated w
from Farooq et al. (13). BMI ¼ body mass index; CrCl ¼ creatinine clearance; CVA ¼
myocardial infarction; Prev ¼ previous; PVD ¼ peripheral vascular disease; STEMI ¼
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; TIA ¼ transienStatistical analysis. Continuous variables are expressed as
means SD or medians and interquartile ranges (IQR), as
appropriate. Binary variables are expressed as counts and/or
percentages. The possible nonlinearity of the continuous
predictors of the Core Model with 1-year all-cause death in
the ACUITY trial were assessed with restricted cubic spline
functions. These are ﬂexible functions that can accommo-
date curves in the form of the association to assess the
assumption that patient characteristics are linearly related to
the log odds of the outcome event (23,25). Statistical anal-
yses were performed with R software (24) and SPSS (version
17.0, SPSS Inc., Chicago, Illinois).
Calibration, discrimination, and clinical usefulness. Calibra-
tion, discrimination, and clinical usefulness (23) were
assessed for the Logistic Clinical SYNTAX score (Core and
Extended Models) and anatomical SYNTAX score in the
ACUITY trial. Calibration refers to the agreement between
observed and predicted outcomes. The possible over- or
underestimation of the predicted risks were graphicallybles) are illustrated. *SYNTAX-like patient deﬁned as fulﬁlling the enrollment
ith 1-, 2-, or 3-vessel disease) or 3-vessel disease alone. Adapted, with permission,
cerebrovascular accident; DM ¼ diabetes mellitus; LV ¼ left ventricular; MI ¼
ST-segment elevation myocardial infarction; SYNTAX ¼ Synergy Between
t ischemic attack.
Table 1. Baseline Characteristics of Patients in the ACUITY Trial
(N ¼ 2,627)
Clinical characteristics
Age, yrs 60.7  11.7 (2,627)
Male 67.5 (1,774/2,627)
Diabetes 28.5 (745/2,614)
Insulin-treated diabetes 7.8 (205/2,614)
Hypertension 65.6 (1,718/2,619)
Hyperlipidemia 56.2 (1,454/2,588)
Cerebrovascular event: previous stroke/transient
ischemic attack
5.8 (150/2,604)
Creatinine clearance, ml/min 99.2  51.8 (2,458)
History of renal insufﬁciency 15.5 (381/2,458)
Left ventricular ejection fraction, % 54.5  12.0 (2,231)
Current smoker 35.3 (925/2,618)
Previous PCI 44.0 (1,155/2,623)
Anatomical/procedural characteristics
Anatomical SYNTAX score 9.0 (IQR 5.0–16.0)*
3-vessel disease 39.7 (1,043/2,627)
Left anterior descending artery involvement 77.5 (2,036/2,627)
Left circumﬂex involvement 66.1 (1,737/2,627)
Right coronary artery involvement 73.8 (1,939/2,627)
Left main involvement 0.5 (12/2,627)
Bare-metal stent implantation 14.0 (369/2,627)
Drug-eluting stent implantation: Cypher or Taxusy 84.9 (2,230/2,627)
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740assessed with validation plots. Discrimination was studied
with the concordance (C) index, which is identical to the
area under the receiver-operating characteristic curve. The
C-index estimates the probability that, of two randomly
chosen patients, the patient with the more favorable prog-
nostic score will outlive the patient with the less favorable
prognostic score, and ranges from 0.5 (no discrimination) to
a theoretical maximum of 1.
Clinical usefulness was assessed using decision curve
analyses (26–29). These analyses estimate a “net beneﬁt” for
prediction models that provide individual risk estimates.
Patients are classiﬁed as high or low risk at a chosen
threshold value. The net beneﬁt considers the beneﬁt of
the classiﬁcation (patients correctly classiﬁed as dying within
1 year) and the harms (patients wrongly classiﬁed as dying
within 1 year). The threshold value for classiﬁcation is used
in the decision-curve analysis to weigh correctly classiﬁed
patients against wrongly classiﬁed patients. The references
were that everyone was classiﬁed as high risk (i.e., died at
1 year), or that everyone was classiﬁed as low risk (i.e., alive
at 1 year). The interpretation of the decision curve is that the
model with the highest net beneﬁt, at a particular threshold
value, is the preferred model.Cypher (sirolimus-eluting stent) only 46.8 (1,043/2,230)
Taxus (paclitaxel-eluting stent) only 49.6 (1,106/2,230)
Cypher and Taxus 1.6 (35/2,230)
Non–ST-segment elevation ACS characteristics
ST-segment deviation 1 mm 25.4 (667/2,627)
Baseline cardiac biomarker elevation 60.2 (1,470/2,442)
Non–ST-segment elevation myocardial infarction 62.2 (1,467/2,358)
Previous myocardial infarction 29.1 (749/2,576)
TIMI risk score (30)
Low: 0–2 16.2 (345/2,131)
Intermediate: 3–4 59.2 (1,261/2,131)
High: 5–7 24.6 (525/2,131)
Values are mean  SD (N), % (n/N), or median (IQR). *Data not normally distributed. yThe
Cypher stent is manufactured by Cordis (Miami Lakes, Florida) and Taxus is manufactured by
Boston Scientiﬁc (Natick, Massachusetts).
ACS ¼ acute coronary syndromes; ACUITY ¼ Acute Catheterization and Urgent Intervention
Triage Strategy; IQR ¼ interquartile range; PCI ¼ percutaneous coronary intervention;
SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac
Surgery; TIMI ¼ Thrombolysis In Myocardial Infarction.Results
The incidence of all-cause mortality in the quantitative
coronary angiography–PCI cohort of the ACUITY trial
(n ¼ 2,627) was 2.4% at 1 year (62 deaths). Baseline char-
acteristics are shown in Table 1 (30). The mean age was
60.7  11.7 years; 33% were women; 62% of patients pre-
sented with non–ST-segment elevation myocardial infarc-
tion and the remainder with unstable angina. Approximately
85% of patients were implanted with DES, and 14%
implanted with BMS. The median anatomical SYNTAX
score was 9.0 (IQR: 5 to 16) with a maximum value of 59.5.
Approximately 40% of the study population had 3-vessel
disease, and 28.5% had diabetes mellitus.
The univariate associations of the variables in the Core
Model (age, CrCl, LVEF, anatomical SYNTAX score) with
1-year mortality in the ACUITY trial are illustrated in Fig. 2.
Validation of the Logistic Clinical SYNTAX score. CALI-
BRATION. For the anatomical SYNTAX score, a good
agreement was found between observed and predicted
mortality outcomes (Fig. 3). For the Logistic Clinical
SYNTAX score (Fig. 3), the Core Model demonstrated
good agreement between observed and predicted mortality
outcomes at the lower risks, with some underestimation at
the higher risks (>5%). The Extended Model demonstrated
good agreement between observed and predicted mortality
outcomes across all recorded risk ranges.
DISCRIMINATION. The area under the receiver-operating
characteristic curve demonstrated a substantially higherpredictive accuracy of the Core and Extended Models for
1-year all-cause death, compared with the anatomical
SYNTAX score in isolation (Fig. 4).
CLINICAL USEFULNESS. The net beneﬁt of the Core and
Extended Models, and the anatomical SYNTAX score, are
shown on the y-axis on the decision curves (Fig. 5). The net
beneﬁt was highest for the Extended Model across all
potential threshold values of 1-year mortality. This was
followed by the Core Model, and then the anatomical
SYNTAX score.
Figure 2. Plots Showing the Form of the Univariate Associations Among the 4 Continuous Core Model Predictors and 1-Year Risk of Death in the ACUITY Trial
Each panel depicts the risk of 1-year death (solid curve)with 95% conﬁdence intervals (dotted curves). A histogram illustrating the distribution of the data for each variable
in the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial is shown below each plot. Due to the rounding of some values of data by the study sites,
for example, left ventricular ejection fraction (often to the nearest 5% or 10%), age (nearest whole integer), or the maximum value being a whole or half point (SYNTAX
[Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery] score), gaps between the values in the histogram for these variables are seen.
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741Discussion
In this study, the Logistic Clinical SYNTAX score was vali-
dated in a large, prospective, randomized trial of patients with
predominantly moderate- and high-risk non–ST-segment
elevation ACS undergoing PCI (8). These ﬁndings indicate
that the Logistic Clinical SYNTAX score is statistically
robust, having previously been cross-validated (“internal-
external” validation procedure [31]) during development in
>6,000 patients in 7 contemporary stent trials (13). The
current study provides further legitimacy toward the clinical
application of the Logistic Clinical SYNTAX score. In
addition, there are several notable ﬁndings: 1) In patients
with non–ST-segment elevation ACS, both the Core (age,
CrCl, LVEF, and anatomical SYNTAX score) and Extend-
ed Models (Core Model and additional 6 variables) substan-
tially improved the predictive accuracy of 1-year mortality
predictions, compared with the anatomical SYNTAX score
alone. 2) The Core and ExtendedModels were both shown to
discriminate well in the study population; the Core Model
underestimated mortality predictions in patients at higher
risk (>5%), which the Extended Model corrected for. 3)Decision-curve analyses, a method to assess clinical useful-
ness, conﬁrmed the progressive improvement in 1-year
mortality predictions over a wide range of thresholds, with the
Extended Model versus the Core Model versus the anatom-
ical SYNTAX score.
One of the main messages of the present study, and of
the previous development and cross-validation study of the
Logistic Clinical SYNTAX score (13), was that the Core
Model was shown to contain most of the predictive infor-
mation for 1-year mortality. The Extended Model, which
incorporates 6 additional clinical variables to the Core
Model, including diabetes and peripheral vascular disease,
yielded only modest incremental improvement for 1-year
mortality predictions. However, the Extended Model proved
to be of additional clinical value in patients with non–ST-
segment elevation ACS in improving the accuracy of higher
risk predictions (>5%), as shown by the validation plots
(Fig. 3). In addition, the decision-curve analyses showed
that the Extended Model provided additional clinical value
compared with the Core Model, by improving the accuracy
of 1-year mortality predictions across all considered risk
threshold values (Fig. 5).
Figure 3. Validation Plots
Validation plots, comparing the anatomical SYNTAX score against the Core and Extended Models of the Logistic Clinical SYNTAX score. A histogram illustrating the
distribution of the predicted risks in the ACUITY trial are shown below each plot (scale not shown). The triangles indicate the observed frequencies by quintiles of the
predicted 1-year risk. Abbreviations as in Figures 1 and 2.
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742Decision-curve analyses were recently proposed as an
assessment of clinical usefulness and weigh the harms (false
positives) against the beneﬁts (true positives) of using a risk
score to make treatment decisions (27,29). Comparatively,
the C-index is the probability of the correct ordering of risks
(i.e., of 2 randomly chosen patients, the patient with the
lower prognostic score will outlive the patient with the
higher prognostic score), and has previously been suggested
to be insensitive in detecting the clinical value of a risk
prediction score (23,29,32,33). Indeed, in the present study,
only a minor increase in the C-index was observed, when
comparing the Extended and Core Models (C-index:
Extended Model: 0.77, Core Model: 0.74) (Fig. 4).
Nevertheless, as the Core Model retained a substantial
superior ability over the anatomical SYNTAX score in
predicting 1-year mortality, the Core Model can be used
with reasonable accuracy, with the knowledge that the
Extended Model would improve the mortality predictions,
particularly in the higher-risk ranges.
Diabetic patients. The FREEDOM (Future Revasculariza-
tion Evaluation in Patients With Diabetes Mellitus: Optimal
Management of Multivessel Disease) trial has recently re-
ported that diabetics with multivessel disease (predominantly
3- vessel disease, without left main involvement), to confer
a mortality beneﬁt in undergoing coronary artery bypass graft
surgery compared with PCI with DES (34). The presentstudy provides insights to the potential importance of dia-
betes as a risk factor for PCI. With the Logistic Clinical
SYNTAX score, diabetes added only minor improvement to
the predictive accuracy of the Core Model, as 1 of 6 other
variables in the ExtendedModel. Essentially the CoreModel
captures most of the patient comorbidity, with variables
such as CrCl, and is therefore likely to be a reﬂection of
the presence of systemic and coronary atherosclerotic
burden. Evidence to support this hypothesis comes from a
population-level cohort study, demonstrating that the rate
of myocardial infarction was substantially higher in nondia-
betics with chronic kidney disease than in diabetics without
chronic kidney disease (35). In addition, a recently published
large meta-analysis demonstrated the importance of kidney
disease as a predictor of clinical outcomes, including mor-
tality, irrespective of the presence or absence of diabetes (36).
Thus, the outcomes for patients with diabetes after PCI may
be favorable if end-organ manifestations of diabetes are not
yet present, such as chronic kidney disease (37).
Study limitations. The ACUITY trial population had rela-
tively low anatomical SYNTAX scores. This is likely to be
representative of real-world practice, because other contem-
porary, all-comer stent trials reported similarmean anatomical
SYNTAX scores to those of the ACUITY trial (17,19–22).
Despite this limitation, 3-vessel disease still represented
approximately 40% of the study population in the ACUITY
Figure 4. ROC Curves
Receiver-operating characteristic (ROC) curves for the anatomical SYNTAX
(Synergy Between Percutaneous Coronary Intervention With Taxus and
Cardiac Surgery) score and the Core and Extended Models of the Logistic
Clinical SYNTAX score, predicting 1-year mortality. The combination of vari-
ables in the Core (red) and Extended (green) Models improves the predictive
performance of the Logistic Clinical SYNTAX score for 1-year mortality.
AUC ¼ area under curve; CI ¼ conﬁdence interval(s).
Figure 5. Decision Curves Demonstrating Identiﬁcation of Patients Who
Will Die, Based on 1-Year Mortality Predictions of Logistic Clinical SYNTAX
Score, Compared With the Anatomical SYNTAX Score
The x-axis shows threshold values for 1-year mortality risk. The clinicianmay use
the threshold to classify patients as high or low risk at a value to proceed with
some action, such as, increased patient monitoring or additional medical
therapy. The y-axis represents the net beneﬁt for the different threshold values
of 1-year mortality risk. The interpretation of the net beneﬁt is in units of true
positives and is the sum of howmany patients are correctly identiﬁed to be high
risk (true positive, i.e., died within 1 year) minus a weighted number of patients
incorrectly identiﬁed as high risk (false positive, i.e., alive at 1 year). The slanted
gray line represents the classiﬁcation of all patients as high risk (i.e., died within
1 year); the horizontal line represents the classiﬁcation of all patients as low risk
(i.e., alive at 1 year), with the latter resulting in a net beneﬁt of 0. The intersection
of the y-axis and the slanted gray line (as highlighted) represents the overall
1-year mortality risk in the ACUITY trial (2.4%). The prediction models that are
the farthest away from the slanted gray line (i.e., assume all died within 1 year)
and the horizontal line (i.e., assume all are alive at 1 year) demonstrate the
highest net beneﬁt, namely the ExtendedModel (broken green line), followed
by the Core Model (broken red line), and then the anatomical SYNTAX score
(broken black line). For example, at a threshold value of 3%, the Extended
Model would correctly identify an extra 1 in 200 deaths, compared with the
anatomical SYNTAX score alone (difference in net beneﬁt is 0.5%). At threshold
values of 5% or 10%, this value would be 1 in 300 (difference in net beneﬁt
0.33%). Abbreviations as in Figures 1 and 2.
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743trial. Second, BMS were used in only 14% of the study pop-
ulation, whereas the Logistic Clinical SYNTAX score was
developed and cross-validated in patients undergoing DES
implantation (13). The validation process was rerun in the
ACUITY trial with BMS patients excluded, and the predic-
tive performance of the Logistic Clinical SYNTAX score did
not change (data not shown). Third, because the present
study assessed ﬁrst-generation DES, we cannot exclude the
possibility of improved mortality with newer generation
DES. In the original development and cross-validation study
of the Logistic Clinical SYNTAX score, composed of 7
contemporary stent trials and >6,000 patients, stent genera-
tion (ﬁrst against newer generation) was not shown to have an
impact on 1-year mortality (13). Conversely, newer genera-
tion DES have been associated with reductions in deﬁnite
stent thrombosis and composite clinical outcomes; however,
improvements in mortality have not been shown (38,39). In
addition, we cannot exclude the possibility of newer genera-
tion antiplatelet therapy to have had an impact on clinical
outcomes (40). Fourth, cardiogenic shock is an important
subset of patients that cannot be assessed with the LogisticClinical SYNTAX score, due to under-recruitment of these
patient types in all-comer stent trials, predominantly due to
the inability to gain appropriate informed consent (13,41).
Lastly, we cannot exclude the possibility of the addition of
a functional component to the calculation of the anatomical
SYNTAX score to improve the predictive accuracy of the
Logistic Clinical SYNTAX score (42).Conclusions
Compared with the anatomical SYNTAX score alone, the
Core and Extended Models of the Logistic Clinical
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744SYNTAX score more accurately predict individual 1-year
mortality in patients presenting with non–ST-segment
elevation ACS undergoing PCI. These ﬁndings provide
further legitimacy toward the clinical application of the
Logistic Clinical SYNTAX score.
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